equasym xr 30 mg; retardkapseln equasym xr 30 mg; retardkapseln
takeda pharma ag - methylphenidati hydrochloridum - equasym xr 30 mg; retardkapseln - methylphenidati hydrochloridum 30 mg, sacchari sphaerae corresp. saccharum 102.3-149.8 mg et maydis amylum, povidonum, hypromellosum, macrogola, ethylcellulosum, dibutylis sebacas, kapselhülle: gelatina, e 132, e 171, e 172 (rubrum), drucktinte: lacca, propylenglycolum, natrii hydroxidum, povidonum, ammoniae solutio 28 per centum, e 171, e 172 (nigrum) pro capsula. - adh, tdah - synthetika
elaprase 2 mg/ml infusionskonzentrat
takeda pharma ag - idursulfasum - infusionskonzentrat - idursulfasum 2 mg, natrii chloridum, dinatrii phosphas heptahydricus, natrii dihydrogenophosphas monohydricus, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 1 ml corresp. natrium 3.7 mg. - traitement à long terme des patients avec-le syndrome de hunter (mucopolysaccharidose de type ii, mps ii) - biotechnologika
edarbi 20mg comprimés
takeda pharma ag - azilsartanum medoxomilum - comprimés - azilsartanum medoxomilum 20 mg ut azilsartanum medoxomilum kalicum 21.34 mg, mannitolum, acidum fumaricum, natrii hydroxidum, hydroxypropylcellulosum, carmellosum natricum conexum, cellulosum microcristallinum, magnesii stearas, pro compresso, natrium 0.80 mg. - essentielle hypertonie - synthetika
edarbi 40mg comprimés
takeda pharma ag - azilsartanum medoxomilum - comprimés - azilsartanum medoxomilum 40 mg ut azilsartanum medoxomilum kalicum 42.68 mg, mannitolum, acidum fumaricum, natrii hydroxidum, hydroxypropylcellulosum, carmellosum natricum conexum, cellulosum microcristallinum, magnesii stearas, pro compresso, natrium 1.60 mg. - essentielle hypertonie - synthetika
edarbi 80mg comprimés
takeda pharma ag - azilsartanum medoxomilum - comprimés - azilsartanum medoxomilum 80 mg ut azilsartanum medoxomilum kalicum 85.36 mg, mannitolum, acidum fumaricum, natrii hydroxidum, hydroxypropylcellulosum, carmellosum natricum conexum, cellulosum microcristallinum, magnesii stearas, pro compresso, natrium 3.20 mg. - essentielle hypertonie - synthetika
intuniv 1 mg retardtabletten
takeda pharma ag - guanfacinum - retardtabletten - guanfacinum 1 mg ut guanfacini hydrochloridum, hypromellosum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii laurilsulfas corresp. natrium 0.03570261 mg, polysorbatum 80, cellulosum microcristallinum, silica colloidalis anhydrica, lactosum monohydricum 23.59 mg, povidonum k 30, crospovidonum, glyceroli dibehenas, acidum fumaricum, pro compresso. - le tdah chez les enfants et les jeunes (6-17 ans) - synthetika
intuniv 2 mg retardtabletten
takeda pharma ag - guanfacinum - retardtabletten - guanfacinum 2 mg ut guanfacini hydrochloridum, hypromellosum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii laurilsulfas corresp. natrium 0.071402 mg, polysorbatum 80, cellulosum microcristallinum, silica colloidalis anhydrica, lactosum monohydricum 47.18 mg, povidonum k 30, crospovidonum, glyceroli dibehenas, acidum fumaricum, pro compresso. - le tdah chez les enfants et les jeunes (6-17 ans) - synthetika
intuniv 3 mg retardtabletten
takeda pharma ag - guanfacinum - retardtabletten - guanfacinum 3 mg ut guanfacini hydrochloridum, hypromellosum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii laurilsulfas corresp. natrium 0.04073661 mg, polysorbatum 80, cellulosum microcristallinum, silica colloidalis anhydrica, lactosum monohydricum 39.80 mg, povidonum k 30, crospovidonum, glyceroli dibehenas, acidum fumaricum, e 132, e 172 (flavum), pro compresso. - le tdah chez les enfants et les jeunes (6-17 ans) - synthetika
intuniv 4 mg retardtabletten
takeda pharma ag - guanfacinum - retardtabletten - guanfacinum 4 mg ut guanfacini hydrochloridum 4.56 mg, hypromellosum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii laurilsulfas corresp. natrium 0.054581 mg, polysorbatum 80, cellulosum microcristallinum, silica colloidalis anhydrica, lactosum monohydricum 53.07 mg, povidonum k 30, crospovidonum, glyceroli dibehenas, acidum fumaricum, e 132, e 172 (flavum), pro compresso. - le tdah chez les enfants et les jeunes (6-17 ans) - synthetika
alunbrig
takeda pharma a/s - brigatinib - carcinome, poumon non à petites cellules - agents antinéoplasiques - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.